Breaking News
5 hours ago
Vaibhavi M.
Medicus Pharma appoints President Carolyn Bonner as CFO, strengthening leadership continuity as the company advances its clinical development programs.
Vaibhavi M.
Regeneron and Tessera partner to advance TSRA-196, a one-time Gene Writing therapy targeting the root cause of alpha-1 antitrypsin deficiency.
Vaibhavi M.
Kiora secures a new USPTO patent for KIO-104’s novel formulation, supporting its Phase 2 development for retinal inflammation and macular edema treatment.
Vaibhavi M.
EU approves Dupixent for moderate-to-severe chronic spontaneous urticaria, offering a first-line biologic option for patients uncontrolled on antihistamines.
Simantini Singh Deo